From a therapeutic viewpoint, inhibition of glycolysis in UCP2 expressing tumours or specific inhibition of UCP2 are, respectively, attractive strategies to target the specific metabolic signature of cancer cells or enhance the effectiveness of ROS-inducing agents. The gene discussed is UCP2; the disease is cancer.